Call Us Today! (800)-424-1338 |

$1.5 Million EBITDA, Multi-location, Multi-State Mental Health Opportunity in the Pacific Northwest


Not Disclosed


Behavioral Health, Mental Health, & ABA Therapy

Asking Price:




Listing Code:

Company Overview

American Healthcare Capital is pleased to exclusively introduce an industry-leading Mental Health Services provider in the Pacific Northwest that is for sale. The company is focused on modern patient care and solutions, including Transcranial Magnetic Stimulation, Psychotherapy, Medication Management, and Spravato (esketamine) Therapy.

The Company provides critical mental health services to its diversified patient base, working with most commercial insurance plans as well as Medicaid, Medicare, TRICARE, and TriWest. In addition, the Company is also in-network for Care Oregon.

Over 100 million people in the U.S. are suffering from depression and anxiety. In 2022, 55% of adults and 60% of youth with severe depression did not receive treatment, mainly due to the limited access and availability of medication management and psychotherapy clinics, often not accepting new patients. Currently in the Pacific Northwest, 80% of mental health medications are prescribed by primary care. To aggravate this situation, 29% to 49% of depressed patients suffer from treatment-resistant depression with no benefit and/or negative side effects from medication. Through multiple locations strategically located across the Pacific Northwest, the Company helps these patients to access state-of-the-art treatment plans, and technologies, in association with a tailored medication management plan, based on the patient’s response to treatment.

Financial Overview

Based on the combined sales of all managed locations in 2021 and the projected full-year consolidated results for 2024, the Company has grown revenue from $2.8 million to $5.5 million, translating into an 18.6% compound annual growth rate (“CAGR”). For the same period, Gross Profit has grown 17.6% CAGR from $1.7 million in 2021 to $3.2 million projected for 2024. Adjusted EBITDA is expected to be $1.5 million in 2024 (27%).

The Management has recognized that the Company is at a critical point in its development. Having achieved their targeted results from the successful creation of multiple de novo locations and the effective implementation of an integrated management system based on physicians’ education, marketing, and outreach programs, the group wishes to see the Company expand its growth horizon through a more aggressive approach to new business development in its core and ancillary services. This includes a comprehensive strategy for further growth through acquisition and de novo clinics. As a result, the shareholders have decided to explore an exit of the Company and have engaged American Healthcare Capital as the exclusive advisor. The management is open to all types of deal structures, including earnout and roll-over equity.

Asking Price

The asking price for this opportunity is $12 million.

Inquire About This Listing

In order to learn more about our listing, you must:

  1. Complete a Buyer Profile

    This profile will be used to pre-qualify buyers and determine whether we can share additional details about our listings. If you have already completed a Buyer Profile, disregard. YOU ONLY NEED TO COMPLETE A BUYER PROFILE ONCE. 

  1. Sign NDA with Listing Code
    To learn more about this listing, you must sign an NDA. When completing the NDA, you will need to copy the exact LISTING CODE and LISTING TITLE.

Listing Code

Listing Title


Scroll to Top